LONDON, September 20, 2013 /PRNewswire/ --
On Thursday, September 19, 2013, the U.S equity markets ended on a mixed note with the S&P 500 closing at 1,722.34, down 0.18%; the Dow Jones Industrial Average ending at 15,636.55, down 0.26%; while the NASDAQ Composite closed at 3,789.38, up 0.15%. Shares in the biotechnology industry mostly ended lower, even as the broader market finished on a mixed note. The major movers in the sector included Amgen Inc. (NASDAQ: AMGN), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), PDL BioPharma Inc. (NASDAQ: PDLI), and Questcor Pharmaceuticals Inc. (NASDAQ: QCOR). AAAResearchReports.com has completed their technical analysis on AMGN, BCRX, PDLI, and QCOR and these free reports are accessible by registering at:
On Thursday, Amgen Inc.'s shares edged lower to end the day at $117.18, which is 0.29% lower than the previous day's closing price of $117.52. The company's shares fluctuated between $115.66 and $117.85 during the trading session. A total of 3.03 million shares were traded, which is below the daily average volume of 3.32 million. Despite Thursday's decline, Amgen Inc.'s shares have surged 12.17% in the last one month and 18.15% in the previous three months, outperforming the S&P 500 which has advanced 4.63% and 5.73% during the respective periods. Further, the company's stock is trading near its 52-week high of $117.91 as well as above its 50-day and 200-day moving averages of $108.84 and $98.81, respectively. Sign up for free technical research on AMGN at:
BioCryst Pharmaceuticals Inc.'s stock gained 0.74% on Thursday, even as the broader market fluctuated between gains and losses. The company's shares oscillated between $6.72 and $6.94 before finishing the day at $6.79. A total of 1.08 million shares were traded, which is below the daily average volume of 2.44 million. Furthermore, BioCryst Pharmaceuticals Inc.'s stock is trading near its 52-week high of $7.41 as well as above its 50-day and 200-day moving average of $5.17 and $2.48, respectively. The company's shares have rallied 297.08% in the previous three months and 23.91% in the last one month, compared to a gain of 5.73% and 4.63% in the S&P 500 during the same period. Be sure to read our latest technical research on BCRX by registering at:
Shares in PDL BioPharma Inc. edged lower on Thursday, even as the broader market ended on a mixed note. The company's shares fluctuated between $8.00 and $8.20 before closing the day 0.43% lower at $8.08. A total of 1.13 million shares were traded, which is less than the daily average volume of 1.79 million. The company's shares have gained 2.54% in the previous three trading sessions and 5.07% in the last three months, compared to a gain of 1.46% and 5.73% in the S&P 500 during the respective period. Further, PDL BioPharma Inc.'s stock has moved closer to its 52-week high of $8.48 as well as above its 50-day and 200-day moving averages of $8.06 and $7.61, respectively. Sign up and read the complimentary report on PDLI at:
The Questcor Pharmaceuticals Inc.'s stock plummeted on Thursday, reversing all gains from the previous trading session. The company's shares ended the day 7.54% lower at $60.68 after fluctuating between $60.56 and $65.77. A total of 2.61 million shares were traded, which is above the daily average volume of 1.59 million. Despite the recent losses, Questcor Pharmaceuticals Inc.'s shares have rallied 27.86% in the previous three months, outperforming the S&P 500 which has advanced 5.73% during the same period. Additionally, the company's stock is trading above its 200-day moving average of $39.56. The free report on QCOR can be downloaded by signing up now at:
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE AAA Research Reports